Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Clinical trial NCT06284460 · WITHDRAWN

Trial details

NCT number: NCT06284460
Sponsor: M.D. Anderson Cancer Center
Status: WITHDRAWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Pathway Mutant Myelodysplastic Syndromes Myelodysplastic Neoplasm Myeloproliferative Neoplasm

Start date: 2025-01-31
Primary completion: 2025-12-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.